AstraZeneca signs MoU with RSSDI

Empowering 1 crore Indian Diabetic patients by 2023 – AstraZeneca signs MoU with RSSDI

A memorandum of understanding (MoU) was signed by AstraZeneca India with the Research Society for Study of Diabetes in India (RSSDI) to empower 1 crore diabetic patients by 2023. This MoU is intended at digitizing and driving proper awareness of Diabetes among the population to stop complexities emerging from the uncontrolled occurrence of the condition.

The Research Society for Study of Diabetes in India is the biggest organization of Diabetes healthcare staff and scientists in Asia, with about 6000 people, including doctors, diabetologists, endocrinologists, and paramedical staff.

The organization has actually contributed extensive research study on Diabetes and continuing diabetes education initiatives in the country. As part of a vital aspect of this collaboration, AstraZeneca revealed a project –‘Beyond Sugar,’ a 3-year patient awareness program established to serve over 1 crore individuals with Diabetic issues throughout the nation. This campaign will certainly enable patients/caregivers to discuss the disease and make choices concerning the control of the disease.

1 in 11 people has Diabetes in south Asia, according to the International Diabetes Foundation Atlas on Diabetic. This shows that India will have around 11.5 crores of diabetic patients by the next 10 years. Research showed that 44% of people hospitalized for Cardiac arrest have type 2 diabetes revealing a high link between Diabetes and Cardiac arrest. And 10-15% of the common population are diabetic. Cardiac arrest is the main health problem in India, with a post-admission fatality of 20-30%.

See Also
Thermo Fishers SARS-CoV-2 GlobalAccess Sequencing Program To Support Research On New Virus Strains

Chronic kidney diseases are correlated with considerable death and a raised risk of cardiac arrest. Consequently, it is vital that Diabetic issues are managed to reduce the occurrence of cardiac arrest and chronic kidney diseases in India.

The company has actually always been at the center of facilitating patient-centric options for controlling non-communicable diseases, stated Dr. Anil Kukreja, Vice President – Medical Affairs and Regulatory, AstraZeneca India. In spite of presently available treatments, the awareness levels amongst the people are fairly low, leading to unrestrained Diabetes and other problems related to the heart and kidneys.

This collaboration will certainly result in enhanced awareness levels about Diabetes and its problems. Ther aim is to reach 1 crore lives in India over the following 3 years via this campaign. During this pandemic, this digitally-powered campaign will certainly enable patients/caregivers to have better discussions with their physicians regarding the disease as well as make notified decisions in controlling Diabetes. This campaign will end up changing the glucose driven management method to a holistic and an early Cardio-Renal centered management of type 2 diabetes, said Dr. Banshi Saboo, President, RSSDI and Organising Chairman 2020.

RSSDI is constantly aimed at raising patient outcomes in Diabetes with consistent study and innovative services. “Beyond Sugar” is one such patient-centric initiative that will play an important role in addition to their RSSDI state chapters to elevate awareness by taking advantage of social networks and digital platforms. With this collaboration, they target to connect to the individuals, neighborhood, and HCP to boost understanding regarding Diabetes as well as aid patients start discussions regarding the prevention of issues in Diabetes, stated Dr. Sanjay Agarwal, Secretary- RSSDI 2020.

See Also
Elon Musk Announces $100 Million Prize For Developing New Carbon Capture Technology

Source

Empowering 1 crore Indian Diabetic patients by 2023 – AstraZeneca signs MoU with RSSDI

Upload your CV to Rasayanika Talent Pool

LEAVE A REPLY

Please enter your comment!
Please enter your name here